Inito, a fertility startup, has raised $29 million in a Series B funding round led by Bertelsmann India Investments (BII), with participation from existing investor Fireside Ventures.
The round brings total equity funding to $45 million.
The fresh funds raised will be used to expand from fertility diagnostics into a broader platform powered by AI-engineered antibodies.
Founded in 2021 by Aayush Rai and Varun AV, Inito was launched as the first fertility monitor. Since then, Inito has become one of the most widely used fertility systems in the world, having analysed more than 30 million hormone data points.
Inito’s flagship fertility monitor captures a continuous dataset of hormone biomarkers at scale, enabling users to measure FSH, Estrogen, LH and PdG (urine metabolite of Progesterone).
Now, Inito is moving beyond fertility to build a broader at-home hormone and health diagnostics platform powered by AI-engineered antibodies.
Aayush Rai and Varun AV, co-founders of Inito, said, “We have always believed that healthcare should start at home. Hormones shape fertility, mood, metabolism, sleep, and energy, yet reliable testing still relies on clinic infrastructure. If you want to understand your hormones, you shouldn’t have to wait weeks for a lab report, you should be able to do it from home, with clinical-grade technology. AI-engineered antibodies allow us to build diagnostic tests that simply were not possible before.”
Swati Murarka, Principal at Bertelsmann India Investments, said, “The future of healthcare lies at the intersection of deep science, AI, and personal wellness — and that’s exactly where Inito is leading. By combining clinical precision with intelligent design, Inito is redefining diagnostics for the modern world. At BII, we’re proud to back visionary founders building globally scalable innovation from India — and Inito exemplifies that ambition.”
Kannan Sitaram, Co-founder & Partner, Fireside Ventures, said, “We have seen Inito evolve from a breakthrough idea into a trusted women’s health brand built on deep consumer insight and scientific accuracy. The team’s ability to deliver clinical-grade insights through a simple and accessible solution has earned strong consumer love. We are proud to reaffirm our partnership as they scale their impact globally.”
